Est.1979
Providing Integrated Research Solutions in Preclinical Biology
| Model | In-vitro model for metabolic stability |
| Test System | Human Liver Microsomes, S9, Hepatocytes |
| Species | Rodent & Non-rodent (as per request) |
| Quantitation method | HPLC-UV or LC/MS/MS |
| Positive control | Suitable substrate |
| Deliverables | Parent compound loss, in-vitro half life |
| Model | In-vitro model for matrix stability |
| Test System | Plasma, serum, blood, CSF, Tissue, aqueous buffers |
| Quantitation method | HPLC-UV or LC/MS/MS |
| Deliverables | Parent compound loss, in-vitro half life |
| Model | In-vitro model for cytochrome P450 Inhibition |
| Test System | Human Liver Microsomes or recombinant enzymes |
| Quantitation method | HPLC-UV or LC/MS/MS or Fluorescence reader |
| Positive control | Suitable substrate |
| End Point | Metabolite formation |
| Deliverables | Percent inhibition, IC50 determination |
| Model | In-vitro model for drug-drug or herb-drug interaction |
| Test System | Human Liver Microsomes or recombinant enzymes |
| Method | Co-incubation of herb-drug or drug-drug with CYP enzymes |
| Quantitation method | HPLC-UV or LC/MS/MS or Fluorescence reader |
| End Point | Metabolite formation |
| Deliverables | Percent inhibition, IC50 determination, Drug interaction potential |
| Model | In-vitro model for CYP450 Reaction Phenotyping |
| Test System | Human Liver Microsomes or recombinant enzymes |
| Quantitation method | HPLC-UV or LC/MS/MS or Fluorescence reader |
| Method | Selective inhibitor for CYP450 – to determine cytochrome P450 involved in metabolism |
| End Point | Metabolite formation |
| Model | In-vitro model for CYP450 Induction |
| Test System | Human Hepatocytes, Cell line (LS180) |
| Quantitation method | LC/MS/MS & RT-PCR |
| Positive Control | Suitable Substrate |
| Method | Determination of enzyme activity and m-RNA levels |
| End Point | Metabolite formation |
| Model | In-vitro model for Plasma Protein Binding |
| Test System | Plasma, serum, whole blood, purified proteins (Albumin, AGP) |
| Species | Rodent and non-rodent (as per request) |
| Quantitation method | LC/MS/MS or HPLC-UV |
| Method | Rapid equilibrium dialysis (RED), Ultrafiltration |
| Deliverables | Percent protein binding |
| Model | In-vitro model for metabolite ID/profiling |
| Test System | Human Liver Microsomes, S9, Hepatocytes |
| Species | Rodent and non-rodent (as per request) |
| Quantitation method | LC/MS/MS or HPLC-UV |
| Deliverables | Metabolite identification/profiling based of m/z found, mass difference from parent compound, possible addition or deletion |
| Model | In-vitro model for determination of Blood to plasma ratio |
| Test System | Whole Blood & Plasma |
| Species | Rodent and non-rodent (as per request) |
| Quantitation method | LC/MS/MS or HPLC-UV |
| Deliverables | Blood to plasma ratio |
| Model | In-vitro model for permeability & Efflux (Caco-2 & MDCK) |
| Test System | Caco-2, MDCK cell lines |
| Method | Unidirectional or bidirectional |
| Quantitation method | LC/MS/MS or HPLC-UV |
| Deliverables | Permeability Coefficient, Efflux ratio |
| Model | In-vitro model for Dermal Absorption/penetration |
| Test System | Rat Skin, Human skin, artificial membranes |
| Quantitation method | LC/MS/MS or HPLC-UV |
| Deliverables | Permeability Coefficient (Kp), Flux |